



Supplemental Fig. S6. Sensitivity analysis of end-stage kidney disease by excluding Perkovic, 2019 (CREDESCENCE) study. (A) Absolute risks and (B) rank probabilities of the treatments. CREDESCENCE, Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation; DPP-4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium-glucose cotransporter 2 inhibitor.